Clinical trial
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
NCT04640532 is registered in ClinicalTrials.gov with Kartos Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
- Lead sponsor
- Kartos Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- November 17, 2020
- Completion date
- July 24, 2025
- Enrollment
- 116 (estimated)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.
myelofibrosis, post-et myelofibrosis, post-pv mf, primary myelofibrosis